Latest Patient Square Capital LP Stock Portfolio
Patient Square Capital LP Performance:
2024 Q4: 0.08%YTD: -11.53%2023: -99.89%
Performance for 2024 Q4 is 0.08%, and YTD is -11.53%, and 2023 is -99.89%.
About Patient Square Capital LP and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Patient Square Capital LP reported an equity portfolio of $267.4 Millions as of 31 Dec, 2024.
The top stock holdings of Patient Square Capital LP are ROIV, LQDA, INSM. The fund has invested 55.2% of it's portfolio in ROIVANT SCIENCES LTD and 8.2% of portfolio in LIQUIDIA CORPORATION.
They significantly reduced their stock positions in LIQUIDIA CORPORATION (LQDA) and PHARVARIS N V (PHVS). Patient Square Capital LP opened new stock positions in INTRA-CELLULAR THERAPIES INC. (ITCI), GERON CORPORATION (GERN) and AGIOS PHARMACEUTICALS, INC. (AGIO). The fund showed a lot of confidence in some stocks as they added substantially to ASTRIA THERAPEUTICS INC (ATXS), ENLIVEN THERAPEUTICS INC and OCULAR THERAPEUTIX, INC. (OCUL).
The top stock holdings of Patient Square Capital LP are ROIV, LQDA, INSM. The fund has invested 55.2% of it's portfolio in ROIVANT SCIENCES LTD and 8.2% of portfolio in LIQUIDIA CORPORATION.
They significantly reduced their stock positions in LIQUIDIA CORPORATION (LQDA) and PHARVARIS N V (PHVS). Patient Square Capital LP opened new stock positions in INTRA-CELLULAR THERAPIES INC. (ITCI), GERON CORPORATION (GERN) and AGIOS PHARMACEUTICALS, INC. (AGIO). The fund showed a lot of confidence in some stocks as they added substantially to ASTRIA THERAPEUTICS INC (ATXS), ENLIVEN THERAPEUTICS INC and OCULAR THERAPEUTIX, INC. (OCUL).
Patient Square Capital LP Annual Return Estimates Vs S&P 500
Our best estimate is that Patient Square Capital LP made a return of 0.08% in the last quarter. In trailing 12 months, it's portfolio return was -11.53%.
New Buys
| Ticker | $ Bought |
|---|---|
| intra-cellular therapies inc. | 6,012,600 |
| geron corporation | 4,677,290 |
| agios pharmaceuticals, inc. | 4,000,110 |
| disc medicine, inc. | 3,575,760 |
| springworks therapeutics, inc. | 3,365,040 |
| allogene therapeutics, inc. | 3,173,510 |
| mirum pharmaceuticals, inc. | 2,683,620 |
| arvinas, inc. | 1,660,640 |
New stocks bought by Patient Square Capital LP
Additions
| Ticker | % Inc. |
|---|---|
| astria therapeutics inc | 166 |
| enliven therapeutics inc | 147 |
| ocular therapeutix, inc. | 99.97 |
| insmed inc | 78.89 |
| intellia therapeutics, inc. | 67.99 |
| nurix therapeutics, inc. | 36.99 |
| cullinan therapeutics inc | 6.57 |
| eyepoint pharmaceuticals | 3.55 |
Additions to existing portfolio by Patient Square Capital LP
Reductions
| Ticker | % Reduced |
|---|---|
| liquidia corporation | -74.1 |
| pharvaris n v | -14.33 |
Patient Square Capital LP reduced stake in above stock
Sold off
Sector Distribution
Patient Square Capital LP has about 95.3% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 95.3 |
| Others | 4.7 |
Market Cap. Distribution
Patient Square Capital LP has about 7.9% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| MID-CAP | 62.9 |
| SMALL-CAP | 24.4 |
| LARGE-CAP | 7.9 |
| UNALLOCATED | 4.7 |
Stocks belong to which Index?
About 40.1% of the stocks held by Patient Square Capital LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 59.9 |
| RUSSELL 2000 | 40.1 |
Patient Square Capital LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Patient Square Capital LP
Patient Square Capital LP has 20 stocks in it's portfolio. About 89.8% of the portfolio is in top 10 stocks. CGEM proved to be the most loss making stock for the portfolio. LQDA was the most profitable stock for Patient Square Capital LP last quarter.
Last Reported on: 14 Feb, 2025| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| AGIO | agios pharmaceuticals, inc. | 1.50 | 121,732 | 4,000,110 | new | |||
| ALLO | allogene therapeutics, inc. | 1.19 | 1,489,910 | 3,173,510 | new | |||
| ARVN | arvinas, inc. | 0.62 | 86,627 | 1,660,640 | new | |||
| ATXS | astria therapeutics inc | 0.35 | 105,057 | 939,210 | added | 166 | ||
| CGEM | cullinan therapeutics inc | 4.00 | 878,897 | 10,705,000 | added | 6.57 | ||
| EYPT | eyepoint pharmaceuticals | 3.93 | 1,410,330 | 10,507,000 | added | 3.55 | ||
| GERN | geron corporation | 1.75 | 1,321,270 | 4,677,290 | new | |||
| INSM | insmed inc | 7.93 | 307,167 | 21,206,800 | added | 78.89 | ||
| ITCI | intra-cellular therapies inc. | 2.25 | 71,990 | 6,012,600 | new | |||
| LQDA | liquidia corporation | 8.18 | 1,860,370 | 21,878,000 | reduced | -74.1 | ||
| MIRM | mirum pharmaceuticals, inc. | 1.00 | 64,900 | 2,683,620 | new | |||
| NRIX | nurix therapeutics, inc. | 3.14 | 446,296 | 8,408,220 | added | 36.99 | ||
| NTLA | intellia therapeutics, inc. | 0.94 | 215,981 | 2,518,340 | added | 67.99 | ||
| OCUL | ocular therapeutix, inc. | 1.50 | 470,919 | 4,021,650 | added | 99.97 | ||
| PHVS | pharvaris n v | 1.49 | 207,603 | 3,979,750 | reduced | -14.33 | ||
| ROIV | roivant sciences ltd | 55.22 | 12,480,000 | 147,638,000 | added | 2.06 | ||
| SRRK | scholar rock holding corporation | 0.52 | 32,000 | 1,383,040 | new | |||
| SWTX | springworks therapeutics, inc. | 1.26 | 93,137 | 3,365,040 | new | |||
| enliven therapeutics inc | 1.89 | 224,038 | 5,040,860 | added | 147 | |||
| disc medicine, inc. | 1.34 | 56,400 | 3,575,760 | new | ||||